Abstract
Riboflavin, which improves energy metabolism similarly to coenzyme Q10 (CoQ10), is effective in migraine prophylaxis. We compared CoQ10 (3 × 100 mg/day) and placebo in 42 migraine patients in a double-blind, randomized, placebo-controlled trial. CoQ10 was superior to placebo for attack-frequency, headache-days and days-with-nausea in the third treatment month and well tolerated; 50%-responder-rate for attack frequency was 14.4% for placebo and 47.6% for CoQ10 (number-needed-to-treat: 3). CoQ10 is efficacious and well tolerated.
Original language | English |
---|---|
Pages (from-to) | 713-715 |
Number of pages | 3 |
Journal | Neurology |
Volume | 64 |
Issue number | 4 |
Publication status | Published - Feb 22 2005 |
ASJC Scopus subject areas
- Neuroscience(all)